132 related articles for article (PubMed ID: 12146719)
1. Optimal two-stage designs for single arm phase II cancer trials.
Shuster J
J Biopharm Stat; 2002 Feb; 12(1):39-51. PubMed ID: 12146719
[TBL] [Abstract][Full Text] [Related]
2. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
3. Interval estimation of binomial proportion in clinical trials with a two-stage design.
Tsai WY; Chi Y; Chen CM
Stat Med; 2008 Jan; 27(1):15-35. PubMed ID: 17566141
[TBL] [Abstract][Full Text] [Related]
4. A predictive probability design for phase II cancer clinical trials.
Lee JJ; Liu DD
Clin Trials; 2008; 5(2):93-106. PubMed ID: 18375647
[TBL] [Abstract][Full Text] [Related]
5. On Simon's two-stage design for single-arm phase IIA cancer clinical trials under beta-binomial distribution.
Liu J; Lin Y; Shih WJ
Stat Med; 2010 May; 29(10):1084-95. PubMed ID: 20077506
[TBL] [Abstract][Full Text] [Related]
6. Optimal adaptive two-stage designs for phase II cancer clinical trials.
Englert S; Kieser M
Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324
[TBL] [Abstract][Full Text] [Related]
7. Admissible two-stage designs for phase II cancer clinical trials.
Jung SH; Lee T; Kim K; George SL
Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
[TBL] [Abstract][Full Text] [Related]
8. Sample size tables for exact single-stage phase II designs.
A'Hern RP
Stat Med; 2001 Mar; 20(6):859-66. PubMed ID: 11252008
[TBL] [Abstract][Full Text] [Related]
9. Optimal adaptive two-stage designs for early phase II clinical trials.
Shan G; Wilding GE; Hutson AD; Gerstenberger S
Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
[TBL] [Abstract][Full Text] [Related]
10. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II clinical trials.
Jung SH; Sargent DJ
J Biopharm Stat; 2014; 24(4):802-16. PubMed ID: 24697589
[TBL] [Abstract][Full Text] [Related]
12. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
Shan G; Zhang H; Jiang T
BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test.
Kwak M; Jung SH
Stat Med; 2014 May; 33(12):2004-16. PubMed ID: 24338995
[TBL] [Abstract][Full Text] [Related]
14. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
Lai X; Zee BC
Trials; 2015 Jun; 16():250. PubMed ID: 26037094
[TBL] [Abstract][Full Text] [Related]
15. Design of Phase II cancer trials evaluating survival probabilities.
Case LD; Morgan TM
BMC Med Res Methodol; 2003 Apr; 3():6. PubMed ID: 12697051
[TBL] [Abstract][Full Text] [Related]
16. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints.
Kunz CU; Kieser M
Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719
[TBL] [Abstract][Full Text] [Related]
17. Optimal, minimax and admissible two-stage design for phase II oncology clinical trials.
Qin F; Wu J; Chen F; Wei Y; Zhao Y; Jiang Z; Bai J; Yu H
BMC Med Res Methodol; 2020 May; 20(1):126. PubMed ID: 32434577
[TBL] [Abstract][Full Text] [Related]
18. Optimal flexible designs in phase II clinical trials.
Chen TT; Ng TH
Stat Med; 1998 Oct; 17(20):2301-12. PubMed ID: 9819829
[TBL] [Abstract][Full Text] [Related]
19. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.
Cellamare M; Sambucini V
Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805
[TBL] [Abstract][Full Text] [Related]
20. Phase II cancer clinical trials with heterogeneous patient populations.
Jung SH; Chang MN; Kang SJ
J Biopharm Stat; 2012; 22(2):312-28. PubMed ID: 22251176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
